SNBI.F Stock Overview
SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
SanBio Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥3.85 |
| 52 Week High | JP¥4.25 |
| 52 Week Low | JP¥3.80 |
| Beta | 0.57 |
| 1 Month Change | 1.32% |
| 3 Month Change | -3.75% |
| 1 Year Change | n/a |
| 3 Year Change | -73.90% |
| 5 Year Change | -87.25% |
| Change since IPO | -54.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| SNBI.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -5.0% | -3.5% |
| 1Y | n/a | -1.7% | 20.2% |
Return vs Industry: Insufficient data to determine how SNBI.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how SNBI.F performed against the US Market.
Price Volatility
| SNBI.F volatility | |
|---|---|
| SNBI.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SNBI.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SNBI.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 65 | Keita Mori | www.sanbio.com |
SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, Parkinson’s disease, spinal cord injury, and Alzheimer’s disease; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis.
SanBio Company Limited Fundamentals Summary
| SNBI.F fundamental statistics | |
|---|---|
| Market cap | US$182.39m |
| Earnings (TTM) | -US$17.10m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-11.1x
P/E RatioIs SNBI.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SNBI.F income statement (TTM) | |
|---|---|
| Revenue | JP¥0 |
| Cost of Revenue | JP¥0 |
| Gross Profit | JP¥0 |
| Other Expenses | JP¥2.64b |
| Earnings | -JP¥2.64b |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -38.53 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 23.8% |
How did SNBI.F perform over the long term?
See historical performance and comparison